Notably, this data compare favorably to an overall median PFS of 4.8 months (range, 1.5–8.3 months) in the same group, suggesting that HER2-targeted CAR-T therapy may benefit specific pancreatic cancer patient populations [159]. Here, ERBB2 is linked to pancreatic neoplasm.